Kenvue Inc. (KVUE)
| Market Cap | 41.74B |
| Revenue (ttm) | 15.46B |
| Net Income (ttm) | 1.06B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.55 |
| PE Ratio | 39.39 |
| Forward PE | 18.22 |
| Dividend | $0.82 (3.77%) |
| Ex-Dividend Date | Nov 13, 2024 |
| Volume | 8,860,763 |
| Open | 21.52 |
| Previous Close | 21.61 |
| Day's Range | 21.47 - 21.97 |
| 52-Week Range | 17.67 - 24.46 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 22.67 (+4.13%) |
| Earnings Date | Feb 6, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Ma... [Read more]
Financial Performance
In 2023, Kenvue's revenue was $15.44 billion, an increase of 3.30% compared to the previous year's $14.95 billion. Earnings were $1.66 billion, a decrease of -19.38%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for KVUE stock is "Hold." The 12-month stock price forecast is $22.67, which is an increase of 4.13% from the latest price.
News
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Secto...
Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
Kenvue's recent earnings showed improvements, but persistent headwinds, especially in the Skin, Health, & Beauty segment, suggest limited upside potential in the near term. Despite solid dividend grow...
Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mon...
67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs
November's top-yielding Aristocrats include Franklin Resources, Amcor, Hormel, and Kenvue, meeting the dogcatcher ideal of dividends from $1K invested exceeding single share prices. Analysts forecast ...
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bon...
Kenvue misses quarterly sales estimates on sluggish skincare sales
Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from...
Kenvue Reports Third Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.
Neutrogena® Launches Breakthrough Collaboration with Two of World's Most Recognizable Dermatologists
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Neutrogena® is establishing multi-year partnerships with Dr. Dhaval Bhanusali, and Dr. Muneeb Shah.
How activist Starboard may help boost value in Kenvue's skin and beauty business
Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Starboard says Kenvue's skin health segment is weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
3-Stock Lunch: Kenvue, UPS & Disney
Sylvia Jablonski, Defiance ETF co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
Investor Hoping To "Band-Aid" KVUE Stock Price
The Wall Street Journal reported that Starboard Value has taken a "sizeable" stake in Kenvue (KVUE) with hopes of matching the company's stock price to competitors. Despite having Tylenol and Band-Aid...
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
Shares of Kenvue (KVUE) took off Monday morning on indications activist investor Starboard Value has taken a large stake in the consumer health products maker.
LUV Proxy Fight, KVUE's New Investor, NOW & UPS Downgrades
Southwest Airlines (LUV) is looking to patch things up with Elliott Investment Management amid a board seat battle, Kenvue (KVUE) gets a new investment from Starboard Value, and Servicenow (NOW) & UPS...
Kenvue shares surge after activist Starboard takes stake
Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's Jeff Smith is expected to detail t...
Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.
Tylenol, Listerine and Band-Aid maker Kenvue has attracted the activist investor, according to a report.
Starboard reportedly takes big stake in Tylenol maker Kenvue
Activist investor Starboard Value has taken a sizeable stake in Kenvue, the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night.
Activist investor Starboard Value takes stake in consumer products maker Kenvue, sources say
Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.
Activist Starboard Value Takes Stake in Tylenol-Maker Kenvue
Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.
Kenvue to Announce Third Quarter 2024 Results on November 7, 2024
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) will announce its third quarter 2024 financial results before market open on November 7, 2024.
Kenvue Declares Quarterly Cash Dividend
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock.
Buy 7 October Dividend Kings, Watch 10 More
A Dividend King is a stock with 50 or more consecutive years of dividend increases per suredividend.com. The 53 Dividend Kings, screened as of October 8, represented 8 of 11 Morningstar Sectors. Broke...
Buy 4 October Dividend Aristocrats & Watch 10
"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024...